Ovarian CA Screening Potentially Cost-Effective in the U.S.

Share this content:
Ovarian CA Screening Potentially Cost-Effective in the U.S.
Ovarian CA Screening Potentially Cost-Effective in the U.S.

FRIDAY, Dec. 8, 2017 (HealthDay News) -- Multimodal screening (MMS) for ovarian cancer is potentially cost-effective in the United States, according to a study published online Dec. 7 in JAMA Oncology.

In an effort to estimate the cost-effectiveness of MMS for ovarian cancer in the United States, Haley A. Moss, M.D., from Duke University in Durham, N.C., and colleagues constructed a Markov simulation model to compare MMS beginning at age 50 years with no screening.

The researchers found that MMS is both more expensive and more effective in reducing ovarian cancer mortality over a lifetime, compared to no screening. MMS of women starting at age 50 years is cost-effective 70 percent of the time when decision makers are willing to pay $150,000 per quality-adjusted life-year, after accounting for uncertainty in the underlying parameters. There was a 15 percent reduction in mortality with screening, with an incremental cost-effectiveness ratio ranging from $106,187 to $155,256.

"These results are limited by uncertainty around the effect of screening on ovarian cancer mortality beyond the 11 years of [the] United Kingdom Collaborative Trial of Ovarian Cancer Screening," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Proinflammatory Diet Linked to Increased Colorectal Cancer Risk

Proinflammatory Diet Linked to Increased Colorectal Cancer Risk

Higher empirical dietary inflammatory pattern score linked to increased risk of CRC for men and women

Longer Duration of Post-Op Opioid Use Associated With Misuse

Longer Duration of Post-Op Opioid Use Associated With ...

Higher dose, shorter duration Rx may minimize risk of longer term misuse, authors say

Alcohol Induced DNA Repair Genes Prognostic in Gastric Cancer

Alcohol Induced DNA Repair Genes Prognostic in Gastric ...

BRF1, BRCA1/2, MPO induced by alcohol have prognostic value for patients with gastric cancer

is free, fast, and customized just for you!

Already a member?

Sign In Now »